NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

NCI renews MUSC Hollings support grant with “outstanding” rating

NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”

April 19, 2024

Vol.50 No.16

Drugs & Targets

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.

April 19, 2024

Vol.50 No.16

Clinical

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

April 12, 2024

Vol.50 No.15

By Jacquelyn Cobb

NCI Director's Report

Rathmell: To improve funding outlook, we must reverse distrust in science

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Health Equity

NCI creates Cancer Equity Leaders group to improve cancer health equity

To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.

April 05, 2024

Vol.50 No.14

By Matthew Bin Han Ong

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

YOU MAY BE INTERESTED IN

NCI renews MUSC Hollings support grant with “outstanding” rating

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

Rathmell: To improve funding outlook, we must reverse distrust in science

NCI creates Cancer Equity Leaders group to improve cancer health equity

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

Renew today!

Subscriber content

Login